Goto

Collaborating Authors

New algorithm uses artificial intelligence to help manage type 1 diabetes

#artificialintelligence

Researchers and physicians at Oregon Health & Science University, using artificial intelligence and automated monitoring, have designed a method to help people with type 1 diabetes better manage their glucose levels. The research was published in the journal Nature Metabolism. "Our system design is unique," said lead author Nichole Tyler, an M.D.-Ph.D. student in the OHSU School of Medicine. "We designed the AI algorithm entirely using a mathematical simulator, and yet when the algorithm was validated on real-world data from people with type 1 diabetes at OHSU, it generated recommendations that were highly similar to recommendations from endocrinologists." That's significant because the people with diabetes typically go three to six months between appointments with their endocrinologist.


New algorithm uses artificial intelligence to help manage type 1 diabetes

#artificialintelligence

Researchers and physicians at Oregon Health & Science University, using artificial intelligence and automated monitoring, have designed a method to help people with type 1 diabetes better manage their glucose levels. The research was published in the journal Nature Metabolism. "Our system design is unique," said lead author Nichole Tyler, an M.D.-Ph.D. student in the OHSU School of Medicine. "We designed the AI algorithm entirely using a mathematical simulator, and yet when the algorithm was validated on real-world data from people with type 1 diabetes at OHSU, it generated recommendations that were highly similar to recommendations from endocrinologists." That's significant because the people with diabetes typically go three to six months between appointments with their endocrinologist.


DreaMed wins FDA clearance for AI insulin recommendation technology - Israel News - Jerusalem Post

#artificialintelligence

A person receives a test for diabetes during Care Harbor LA free medical clinic in Los Angeles, California September 11, 2014. DreaMed Diabetes, the Petah Tikva-based developer of personalized diabetes management solutions, has received US Food and Drug Administration (FDA) clearance for its artificial intelligence-powered insulin recommendations technology. The company's AI-based insulin dosing decision-support software, DreaMed Advisor Pro, aims to assist people with Type 1 diabetes (T1D) using insulin-pump therapy with continuous glucose sensors or blood glucose meters.


Using graph database technology to tackle diabetes

ZDNet

Understanding more about diabetes is key to treating and preventing the disease. Germany's DZD centre of diabetic research is using graph database technology from Neo4j to learn more about the illness. ZDNet spoke to DZD's head of data and knowledge management, Dr Alexander Jarasch, to find out more. ZDNet: Can you tell me about your organisation? Jarasch: We are a non-profit organisation doing research on diabetes.


Heart failure risk in diabetics can now be predicted by machine learning derived score

#artificialintelligence

The study was also presented at the Heart Failure Society of America Annual Scientific Meeting in Philadelphia. Type 2 diabetes is a global epidemic that is expected to affect over 592 million people globally by 2035, a dramatic increased from 382 million people with diabetes mellitus in 2013, a prevalence that is likely to be underestimated. Type 2 diabetes patients are at more than double the risk of developing heart failure resulting in disability or death among such patients. Earlier this month, late-breaking trial results revealed that a new class of medications known as SGLT2 inhibitors may be helpful for patients with heart failure. These therapies may also be used in patients with diabetes to prevent heart failure from occurring in the first place.